Neoleukin Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (ticker: NLTX) was a U.S.-based biotechnology company formerly listed on the NASDAQ in the United States. For investors, it is important to note that Neoleukin later completed a merger with Neurogene, after which the company changed its name to Neurogene Inc. and the ticker changed from NLTX to NGNE. As a result, NLTX should be viewed primarily as the legacy identity of the public company rather than a currently standalone operating biotech. ([ir.neurogene.com](https://ir.neurogene.com/node/8826/html?utm_source=openai)) Neoleukin was founded in 2018 and had its principal place of business in New York, New York. Before the merger, it operated as a clinical-stage biotechnology company with a strong research-and-development focus. Like many early-stage biopharma names, its value proposition was based on advancing scientific programs, building internal capabilities, and funding development through equity markets rather than generating meaningful commercial revenue. SEC filing language indicates that the company devoted substantially all of its efforts to R&D, management hiring, administration, and capital raising. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000044/neurogeneannualreport2023.pdf?utm_source=openai)) From an industry-positioning standpoint, Neoleukin belonged to the highly competitive small-cap biotech segment, where investors typically evaluate companies on scientific differentiation, pipeline quality, regulatory milestones, and financing strength. The decisive strategic event in the company’s recent history was the reverse merger announced in July 2023 and closed on December 18, 2023. That transaction combined Neoleukin with Neurogene and effectively transformed the listed entity into a different business profile, centered on Neurogene’s gene-therapy platform and lead programs. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-and-neoleukin-announce-definitive-merger-agreement/?utm_source=openai)) Post-merger, the company’s development focus shifted to Neurogene’s portfolio, including NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. The company also highlighted regulatory tailwinds for NGN-401, including Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the U.S. FDA. For market participants, those details matter because they show the direction of value creation after the Neoleukin period: the legacy cash shell and clinical infrastructure were effectively absorbed into a gene-therapy-led growth story. ([ir.neurogene.com](https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and?utm_source=openai)) Geographically, the business was concentrated in the United States, with leadership and operations centered in New York and a U.S. NASDAQ listing. In practical terms, Neoleukin’s story is best understood as a biotech transition case: a pre-commercial company, founded in 2018, that entered the public markets, pursued clinical development, and then ultimately became part of a broader rare-disease gene-therapy platform. For investors reviewing historical NLTX filings, especially Form 4 insider transactions, the key context is that the symbol represents an earlier corporate phase of an entity that no longer trades under that name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000044/neurogeneannualreport2023.pdf?utm_source=openai))